Fig. 1.
Susceptibility profiles of 20 clinical A_ baumannii isolates_
| Antibiotics | Susceptible | Resistant | ||
|---|---|---|---|---|
| Number | Rate (%) | Number | Rate (%) | |
| Amikacin | 3 | 15.0% | 17 | 85.0% |
| Ceftazidime | 0 | 0.0% | 20 | 100% |
| Ciprofloxacin | 0 | 0.0% | 20 | 100% |
| Levofloxacin | 0 | 0.0% | 20 | 100% |
| Gentamicin | 0 | 0.0% | 20 | 100% |
| Tobramycin | 3 | 15.0% | 17 | 85.0% |
| Ceftriaxone | 0 | 0.0% | 20 | 100% |
| Cefotaxime | 0 | 0.0% | 20 | 100% |
| Cefepime | 0 | 0.0% | 20 | 100% |
| Imipenem | 0 | 0.0% | 20 | 100% |
| Meropenem | 0 | 0.0% | 20 | 100% |
| Trimethoprim/sulfamethoxazole | 6 | 30.0% | 14 | 100% |
| Piperacillin/tazobactam | 0 | 0.0% | 20 | 100% |
| Tigecycline | 20 | 100% | 0 | 0.0% |
| Polymyxin B | 20 | 100% | 0 | 0.0% |
Susceptibility profiles of the airborne and clinical strains with the highest similarity_
| Strain / Antibiotics | TAaba004 | TAaba012 |
|---|---|---|
| Amikacin | R | R |
| Ceftazidime | R | R |
| Ciprofloxacin | R | R |
| Levofloxacin | R | R |
| Gentamicin | R | R |
| Tobramycin | R | R |
| Ceftriaxone | R | R |
| cefotaxime | R | R |
| Cefepime | R | R |
| Imipenem | R | R |
| Meropenem | R | R |
| Trimethoprim/sulfamethoxazole | R | R |
| Piperacillin/tazobactam | R | R |
| Tigecycline | S | S |
| Polymyxin B | S | S |